Funding profile · Healthcare staffing software
Bemlo
A $3.3 million seed round in 2022, no SEC or Swedish securities filing disclosing a price, and five years of small, loss making revenue in the filed accounts of the operating company, Bemalong AB. Here is what the public record actually shows.
$3.3MSeed round, company-reported, closed Aug 2022
$3.78 to 3.83MTotal funding across all rounds, per aggregator data, not company-confirmed
7,962 tkr2025 revenue reported to Sweden’s company register (about $770K)
-4,448 tkr2025 result after financial items, per the same filing (about -$430K)
Data as of September 25, 2026. Company-reported figures are labeled. SEK to USD approximated at 10.3.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| 2020 | Early angel or accelerator funding | $34,000 per one aggregator | Devotion Ventures named separately as an early Swedish backer | Aggregator |
| Winter 2022 | Y Combinator batch (W22) | Not disclosed | Y Combinator | YC data |
| Aug 2, 2022 | Seed | $3.3 million ($3.2 million euro equivalent reported) | Y Combinator, Long Journey Ventures, Uncommon Capital, Goodwater Capital; angels Arash Ferdowsi and Austen Allred; executives from Kry | Company release |
| Feb 20, 2024 | Acquisition of Vivium (Sweden) | Not disclosed | Prior Vivium owners: Hidden Dreams, CEO Peter Westerholm, COO Philip Gustavsson, CPO Andreas Jakubowicz | Company release |
What the filings show
No Form D or other US securities filing for Bemlo or Bemalong AB appears in SEC EDGAR, and none would be expected for a Swedish company raising from non-US-registered instruments. Sweden has no equivalent public disclosure requirement for private seed rounds. What is public is Bemalong AB’s own annual accounts, filed with Sweden’s Companies Registration Office and republished by commercial registries.
Bemalong AB · Annual accounts · fiscal years 2021 to 2025
- Legal name
- Bemalong AB
- Org number
- 559260-6718
- Registered
- Jun 24, 2020
- Share capital
- 25,000 SEK
- Net sales 2021 to 2025
- 1,568 · 6,862 · 4,125 · 5,309 · 5,960 tkr
- Result after financial items 2021 to 2025
- -221 · -6,366 · -15,542 · -9,098 · -4,448 tkr
- Employees (latest filing)
- 7
- Auditor flags
- 2024 accounts: irregular tax or fee payment. 2025 accounts: other serious auditor comments
- CEO and chair
- Alexander Carl Christer Bjorkenstam, born 2000
- Filing
- Sweden’s Companies Registration Office (Bolagsverket), via Allabolag.se
Reading the filings
- The company is small and has never turned a profit.Five straight years of net sales under 8 million SEK, roughly under $800,000 at current rates, with a loss every year. The worst year on record is 2023, a 15.5 million SEK loss against 4.1 million SEK of sales, a loss more than three times revenue.
- Revenue is not a straight line.Sales roughly quadrupled from 2021 to 2022, then fell by 40 percent in 2023, then recovered gradually through 2025. That pattern is consistent with a company that changed its product and customer base, which lines up with the 2024 pivot from a staffing marketplace toward scheduling software plus the Vivium acquisition.
- Two consecutive years drew auditor attention.The 2024 accounts were flagged for irregular payment of taxes or fees, and the 2025 accounts for a separate, unspecified serious matter. Neither flag by itself proves insolvency risk, but two in a row on a small company’s books is worth tracking into the next filing.
- The seed round total is not confirmed by any filing.Every press account of the August 2022 round gives the same $3.3 million figure, sourced to the company’s own announcement, and it is corroborated across at least five independent outlets. No filing breaks that figure down by investor or shows how much of it had actually been received by year end.
- No price is on record for the Vivium deal.The acquisition announcement names Vivium’s prior owners by name but discloses no purchase price, and no public filing fills the gap. PitchBook lists the deal as a merger and acquisition with no deal size shown.
- Headcount estimates disagree by a factor of two or more.Sweden’s own company register shows 7 employees at last filing. Commercial aggregators, which often lag or round differently, show figures from 11 to 50 up to 18 as of a 2026 snapshot. The register figure is the one filed under legal obligation; the others are estimates.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Product shift | From a nurse and doctor jobs marketplace (2022 pitch) to AI scheduling software for healthcare employers (2024 to 2026 pitch), following the Vivium acquisition. | Company-stated |
| Geography | Sweden, Norway and the UK named as active markets in 2022. No later confirmation found that the UK operation is still active. | Not confirmed |
| Customers | Company says its marketplace has been used by tens of thousands of nurses and doctors and that it works with public and private healthcare organizations. No named hospital, clinic or Swedish region customer for the current scheduling product found. | Company-stated |
| Business model | Commission and advertising fees from staffing agencies on the marketplace side, per 2022 press coverage. Pricing for the enterprise scheduling software not disclosed. | Independent |
| Leadership | CEO changed from Benjamin Waye, named CEO in the 2022 seed announcement, to Alexander Bjorkenstam, who holds the title in the 2024 Vivium release and in the current company register. No transition announcement found. | Not confirmed |
What to watch
- The 2026 annual accounts, to see whether the 2025 auditor comment recurs or is resolved.
- Any new funding round. None has been announced since the August 2022 seed.
- Disclosure of Vivium’s acquisition price, if it ever surfaces in a filing or interview.
- Named enterprise customers for the AI scheduling product.
The Bemlo story on Healthcare DiscoveryHealthcare Discovery
Related companies
Sources
- Public recordBemalong AB, org.nr 559260-6718, key figures and annual accounts, 2021 to 2025
- Public recordBemalong AB company overview, registration date, management
- IndependentBemlo 2026 Company Profile: Valuation, Funding and Investors
- IndependentVivium (Sweden) 2026 Company Profile: Valuation, Investors, Acquisition
- IndependentBemlo 2026 Company Profile, Team, Funding and Competitors
- IndependentBemlo Company Profile
- IndependentBemlo Funding, company data summary
- IndependentBemlo to raise $3.3M in a seed round, funding brief
- IndependentBemlo acquires its Stockholm-based competitor Vivium, deal brief
- IndependentStockholm-based Bemlo bags over €3.2 million to tackle the European healthcare labour shortage
- IndependentBemlo gets $3.3 million dosage to solve healthcare labour shortage in Europe
- IndependentVårdplattformen Bemlo tar in miljoner från ängelinvesterare
- CompanyBemlo completes acquisition of Vivium
Compiled from Sweden’s Bolagsverket company register and published reports as of September 25, 2026. Bemalong AB’s annual accounts report figures as filed for each fiscal year and may be restated in later filings. Healthcare Venture Capital Fund holds no position in Bemlo. This page is not an offer to sell or a recommendation to buy any security.